Search results
Results from the WOW.Com Content Network
Aponeurotic fibroma; Infantile digital fibromatosis; Aggressive infantile fibromatosis; Fibromatosis colli: benign sternocleidomastoid muscle tumor developing in infants within 8 weeks (average: 24 days) of delivery. It generally does not require resection and responds well to physiotherapy.
This form of IMF, particularly in cases with tumors involving the gastrointestinal tract, heart, and/or lung, [6] has a far higher morbidity and mortality than the other forms [8] with death occurring in infants during the first weeks to 4 months of life [4] in 30–70% of cases [9] Death is typically due to a tumor's compression of vital ...
Diffuse infantile fibromatosis is a rare condition affecting infants during the first three years of life. This condition is a multicentric infiltration of muscle fibers with fibroblasts resembling those seen in aponeurotic fibromas, presenting as lesions and tumors confined usually to the muscles of the arms, neck, and shoulder area [1]: 607 Diffuse infantile fibromatosis is characterized by ...
Fibromatosis colli (FMC), also termed sternocleidomastoid tumor of infancy, pseudotumor of infancy, [1] and infancy sternocleidomastoid pseudotumor, [2] is an uncommon (incidence: 0.4%–1.3% of live births), congenital tumor in one of the two sternocleidomastoid neck muscles although rare cases have presented with a FMC tumor in both ...
[25] [15] Rarely, amputation may be necessary due to injury caused by the tumor or its treatments. [18] Tumors may be misdiagnosed (30–40%) [25] due to their rarity and a lack of knowledge; patients may initially be given inappropriate treatment or poor prognoses due to misdiagnosis with conditions such as malignant sarcoma.
For example, prostate cancer has a much higher one-year overall survival rate than pancreatic cancer, and thus has a better prognosis. Sometimes the overall survival is reported as a death rate (%) without specifying the period the % applies to (possibly one year) or the period it is averaged over (possibly five years), e.g. Obinutuzumab: A ...
If the coding was accurate, this figure should approximate 1.0 as the rate of those dying of non-cancer deaths (in a population of cancer sufferers) should approximate that of the general population. Thus, the use of relative survival provides an accurate way to measure survival rates that are associated with the cancer in question.
Progression-free survival (PFS) is "the length of time during and after the treatment of a disease, such as cancer, that a patient lives with the disease but it does not get worse". [1] In oncology, PFS usually refers to situations in which a tumor is present, as demonstrated by laboratory testing, radiologic testing, or clinically. Similarly ...